Company / Cost of Revenue
Elanco Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$2.1B
FY2025
5-year range
$1.9B / $2.1B
FY2021-FY2025
Trend
+5.9%
vs FY2024
Sector context
#15 of 85
Health Care
What the data says
Elanco's cost of revenue of $2.1B is higher than 82% of companies in the Health Care sector (FY2025). Cost of Revenue has increased for 3 consecutive years, from $1.9B in FY2022 to $2.1B in FY2025.
Based on SEC 10-K filings.
$2.1B in FY2025 with a 5-year CAGR of +4.9%. Top quartile in the Health Care sector.
Increased from $1.9B to $2.1B over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +3.5%
- 5-Year CAGR
- +4.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 18% in Health CareTop 82% of 85This company $2.1B Sector average $2.0B
▼
+7.0% above sector average
Key checks
Key Insights
- Elanco's cost of revenue has grown for 3 consecutive years.
- 5-year CAGR of +4.9%, indicating consistent growth.
- In FY2025, cost of revenue increased 5.9% year-over-year.
- Ranks #15 out of 85 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.72 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.1B | +5.9% |
| FY2024 | $2.0B | +3.7% |
| FY2023 | $1.9B | +0.9% |
| FY2022 | $1.9B | -10.3% |
| FY2021 | $2.1B | +27.9% |
| FY2020 | $1.7B | +13.4% |
| FY2019 | $1.5B | -6.6% |
| FY2018 | $1.6B | +5.3% |
| FY2017 | $1.5B | +6.0% |
| FY2016 | $1.4B | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026